<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291289</url>
  </required_header>
  <id_info>
    <org_study_id>MO29112</org_study_id>
    <secondary_id>2014-001017-61</secondary_id>
    <nct_id>NCT02291289</nct_id>
  </id_info>
  <brief_title>A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)</brief_title>
  <acronym>MODUL</acronym>
  <official_title>A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, multi-center, active-controlled, open-label, parallel-group study will
      investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line
      mCRC. Participants with mCRC are eligible for entry and cannot have received any prior
      chemotherapy in the metastatic setting. The entire study duration is anticipated to be
      approximately 7.5 years.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 17, 2015</start_date>
  <completion_date type="Anticipated">October 23, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From randomization until disease progression or death from any cause, up to 5 years</time_frame>
    <description>PFS is defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization until death from any cause, up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From baseline until end of study (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response</measure>
    <time_frame>From randomization until disease progression, up to 5 years</time_frame>
    <description>Calculated as the number of participants with a best overall response of CR or PR according to RECIST 1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR= CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From randomization until disease progression, up to 5 years</time_frame>
    <description>DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Response</measure>
    <time_frame>From randomization until disease progression or death from any cause, up to 5 years</time_frame>
    <description>Calculated as the time from randomization to the first Occurrence of a documented Objective Response (CR or PR) determined according to RECIST 1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From first objective response until disease progression or death from any cause, up to 5 years</time_frame>
    <description>Defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score</measure>
    <time_frame>From baseline until end of study (up to 5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">609</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 5-FU/LV,cetuximab,vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: capecitabine,trastuzumab,pertuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Cobimetinib,atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Induction Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Induction Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Induction Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Induction Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500 mg/m^2 via IV infusion on Day 1 of every 2-week cycle</description>
    <arm_group_label>Cohort 1: 5-FU/LV,cetuximab,vemurafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX induction regimen</intervention_name>
    <description>Administered per the Investigator's discretion in accordance with locally approved prescribing information.</description>
    <arm_group_label>Cohort 1: Induction Treatment</arm_group_label>
    <arm_group_label>Cohort 2: Induction Treatment</arm_group_label>
    <arm_group_label>Cohort 3: Induction Treatment</arm_group_label>
    <arm_group_label>Cohort 4: Induction Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoropyrimidine (5-FU/LV or capecitabine)</intervention_name>
    <description>Per Investigator's discretion: 1600-2400 mg/m^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.</description>
    <arm_group_label>Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_label>Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_label>Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab</arm_group_label>
    <arm_group_label>Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_label>Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg</description>
    <arm_group_label>Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab</arm_group_label>
    <arm_group_label>Cohort 4: Cobimetinib,atezolizumab</arm_group_label>
    <other_name>MPDL3280A, RO5541267</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>960 mg vermurafenib BID by mouth</description>
    <arm_group_label>Cohort 1: 5-FU/LV,cetuximab,vemurafenib</arm_group_label>
    <other_name>RO5185426</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information</description>
    <arm_group_label>Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_label>Cohort 1: Induction Treatment</arm_group_label>
    <arm_group_label>Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_label>Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab</arm_group_label>
    <arm_group_label>Cohort 2: Induction Treatment</arm_group_label>
    <arm_group_label>Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_label>Cohort 3: Induction Treatment</arm_group_label>
    <arm_group_label>Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab</arm_group_label>
    <arm_group_label>Cohort 4: Induction Treatment</arm_group_label>
    <other_name>RO4876646</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle</description>
    <arm_group_label>Cohort 3: capecitabine,trastuzumab,pertuzumab</arm_group_label>
    <other_name>RO0452317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle</description>
    <arm_group_label>Cohort 3: capecitabine,trastuzumab,pertuzumab</arm_group_label>
    <other_name>RO4368451</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>60 mg orally once daily for 3 weeks followed by a 1-week treatment break</description>
    <arm_group_label>Cohort 4: Cobimetinib,atezolizumab</arm_group_label>
    <other_name>RO5514041</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU/LV</intervention_name>
    <description>1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first.</description>
    <arm_group_label>Cohort 1: 5-FU/LV,cetuximab,vemurafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG PS of less than or equal to (&lt;=) 2

          -  At least 16 weeks of life expectancy at time of entry into the study

          -  Histologically confirmed colorectal cancer (CRC) with mCRC confirmed radiologically

          -  Measureable, unresectable disease according to RECIST 1.1

          -  No prior chemotherapy for CRC in the metastatic setting

          -  Archival tumor formalin-fixed paraffin-embedded tissue block from the primary tumor
             obtained at the time of the initial diagnosis is available

          -  Adequate hematological, liver and renal function

          -  Agreement to use highly effective measures of contraception

        Exclusion Criteria for All Participants:

          -  Less than 6 months from completion of any prior neoadjuvant or adjuvant chemotherapy,
             radiotherapy

          -  Prior or current treatment with bevacizumab or any other anti-angiogenic drug
             (vascular endothelial growth factor or vascular endothelial growth factor receptor
             therapies or tyrosine kinase inhibitors)

          -  Current or recent (within 10 days of study enrollment) use of aspirin (more than [&gt;]
             325 milligrams per day [mg/day]), clopidogrel (&gt; 75 mg/day), or current or recent
             (within 10 days prior to the start of study induction treatment) use of therapeutic
             oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes
             (prophylactic uses allowed)

          -  Active infection requiring intravenous antibiotics at the start of study induction
             treatment

          -  Previous or concurrent malignancy, except for adequately treated basal or squamous
             cell skin cancer, in situ cervical cancer, or other cancer for which the participant
             has been disease-free for 5 years prior to study entry

          -  Inadequately controlled hypertension; prior history of hypertensive crisis or
             hypertensive encephalopathy

          -  Clinically significant (active) cardiovascular disease, for example cerebrovascular
             accidents &lt;= 6 months prior to start of study induction treatment, myocardial
             infarction &lt;= 6 months prior to study enrollment, unstable angina, New York Heart
             Association (NYHA) Functional Classification Grade II or greater congestive heart
             failure, or serious cardiac arrhythmia uncontrolled by medication or potentially
             interfering with protocol treatment

          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or
             recent arterial thrombosis) within 6 months of start of study induction treatment

          -  Active symptomatic or untreated central nervous system (CNS) metastases; CNS disease
             other than supratentorial or cerebellar metastases (in other words, patients with
             metastases to midbrain, pons, medulla or spinal cord are excluded); history of or
             known carcinomatous meningitis

          -  Known hypersensitivity to any component of any of the study induction or maintenance
             treatment medications

          -  Pregnancy or lactation

        Exclusion Criteria for Participants in Cohort 1 (MP):

          -  Inability to swallow pills

          -  Refractory nausea and vomiting, malabsorption, external biliary shunt or significant
             bowel resection that would preclude adequate absorption

          -  History or presence of clinically significant ventricular or atrial dysrhythmias

          -  Corrected QT (QTc) interval &gt;= 450 millisecond assessed within 3 weeks prior to
             randomization, long QT syndrome or, uncorrectable electrolyte abnormalities (including
             magnesium) or requirement for medicinal products known to prolong the QT interval

          -  ECOG PS &gt; 2

        Exclusion Criteria for Participants in Cohort 2 (MP):

          -  History of autoimmune disease including but not limited to myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
             multiple sclerosis, vasculitis, or glomerulonephritis

          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation

          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
             pneumonitis, organizing pneumonia, or evidence of active pneumonitis at most recent
             chest imaging (computed tomography [CT] scan or magnetic resonance imaging [MRI])

          -  Positive test for human immunodeficiency virus (HIV)

          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) at Screening

          -  Active tuberculosis

          -  Severe infection within 4 weeks prior to start of maintenance treatment including, but
             not limited to, hospitalization for complications of infection, bacteremia, or severe
             pneumonia; has signs or symptoms of significant infection or has received oral or IV
             antibiotics within 2 weeks prior to start of maintenance treatment

          -  Administration of a live, attenuated vaccine within 4 weeks prior to start of
             maintenance treatment or anticipation that such a live attenuated vaccine will be
             required during the remainder of the study

          -  Prior treatment with cluster of differentiation (CD) 137 agonists, anti-cytotoxic
             T-lymphocyte-associated antigen (CTLA) 4, anti-programmed death-1 (PD-1), or
             anti-programmed death-ligand 1 (PD-L1) therapeutic antibody or pathway-targeting
             agents

          -  Treatment with systemic immunostimulatory agents (including but not limited to
             interferons or interleukin-2) within 4 weeks or five half-lives of the drug, whichever
             is longer, prior to start of maintenance treatment

          -  Treatment with systemic corticosteroids or other systemic immunosuppressive
             medications within 2 weeks prior to start of maintenance treatment, or anticipated
             requirement for systemic immunosuppressive medications during the remainder of the
             study

          -  If receiving receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor
             (for example, denosumab) and unwilling to adopt alternative treatment such as
             bisphosphonates while receiving atezolizumab

        Exclusion Criteria for Participants in Cohort 3 (MP):

          -  Inability to swallow pills

          -  Left ventricular ejection fraction (LVEF) less than (&lt;) 50 percent (%) as assessed
             after completion of induction treatment by either 2-dimensional echocardiogram or
             multiple-gated acquisition

          -  Clinically significant cardiovascular disease, including unstable angina, history of
             or active congestive heart failure of ≥ NYHA Grade 2, history of or ongoing serious
             cardiac arrhythmia requiring treatment (except for controlled atrial fibrillation
             and/or paroxysmal supraventricular tachycardia).

          -  Current uncontrolled hypertension with or without medication

          -  Current dyspnea at rest due to complications of advanced malignancy or other disease
             requiring continuous oxygen therapy

          -  Insulin-dependent diabetes

          -  Current known infection with HIV, HBV, or HCV (active infection or carriers)

          -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or
             chemically related analogues, such as brivudine

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function,
             resection of the stomach or small bowel, or ulcerative colitis

          -  Known hypersensitivity to murine proteins

        Exclusion Criteria for Participants in Cohort 4 (MP):

          -  Inability to swallow medications

          -  History of autoimmune disease including but not limited to myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
             multiple sclerosis, vasculitis, or glomerulonephritis

          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
             pneumonitis, organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing
             pneumonia), or evidence of active pneumonitis on most recent chest imaging (CT scan or
             MRI)

          -  Malabsorption condition that would alter the absorption of orally administered
             medications

          -  Amylase or lipase ≥ 1.5 times the upper limit of normal within 14 days prior to
             maintenance treatment initiation

          -  Serum albumin less than (&lt;) 2.5 grams per deciliter (g/dL)

          -  LVEF &lt; institutional lower limit of normal or &lt; 50%, whichever is lower

          -  Poorly controlled hypertension

          -  Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated
             drainage more than once every 28 days. Indwelling drainage catheters are allowed

          -  Unstable angina, new onset angina within last 3 months, myocardial infarction within
             last 6 months and current congestive heart failure ≥ NYHA Grade 2

          -  History of stroke, reversible ischemic neurological defect, or transient ischemic
             attack within 6 months prior to initiation of maintenance treatment

          -  History or evidence of intracranial hemorrhage or spinal cord hemorrhage

          -  Evidence of clinically significant vasogenic edema

          -  Any hemorrhage or bleeding event ≥ National Cancer Institute Common Terminology
             Criteria for Adverse Events Grade 3 within 28 days prior to initiation of maintenance
             treatment

          -  History or evidence of retinal pathology on ophthalmologic examination that is
             considered a risk factor for central serous retinopathy, retinal vein occlusion, or
             neovascular macular degeneration

          -  Positive HIV test

          -  Active HBV or HCV

          -  Active tuberculosis

          -  Severe infection within 4 weeks prior to start of maintenance treatment including, but
             not limited to, hospitalization for complications of infection, bacteremia, or severe
             pneumonia; has signs or symptoms of significant infection or has received oral or IV
             antibiotics within 2 weeks prior to start of maintenance treatment.

          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation

          -  Administration of a live, attenuated vaccine within 4 weeks prior to start of study
             maintenance treatment or anticipation that such a live attenuated vaccine will be
             required during the study

          -  Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic
             antibody or pathway-targeting agents

          -  Prior treatment with a mitogen-activated protein kinase/extracellular signal-regulated
             kinase (ERK) or ERK inhibitor

          -  Treatment with systemic immunostimulatory agents (including but not limited to
             interferons or interleukin-2) within 4 weeks or five half-lives of the drug, whichever
             is longer, prior to start of study maintenance treatment

          -  Treatment with systemic corticosteroids or other systemic immunosuppressive
             medications (including but not limited to prednisone, dexamethasone, cyclophosphamide,
             azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within
             2 weeks prior to start of study maintenance treatment, or requirement for systemic
             immunosuppressive medications during the trial.

          -  If receiving a RANKL inhibitor (for example, denosumab), unwilling to adopt
             alternative treatment such as (but not limited to) bisphosphonates, while receiving
             atezolizumab.

          -  Consumption of foods, supplements or drugs that are potent cytochrome P450 3A4
             (CYP3A4) enzyme inducers or inhibitors ≤ 7 days before initiation of study maintenance
             treatment or expected concomitant use during maintenance treatment. These include St.
             John's wort or hyperforin (potent CYP3A4 enzyme inducer) and grapefruit juice (potent
             CYP3A4 enzyme inhibitor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1264AAA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral (CORI)</name>
      <address>
        <city>La Rioja</city>
        <zip>F5300COE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Viedma</name>
      <address>
        <city>Viedma, Rio Negro</city>
        <zip>8500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet X</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC MontLégia</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta (Campus Wilgenstraat)</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of the Republic of Srpska</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <zip>99010-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFRGS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cancer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Amaral Carvalho</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina de Sao Jose do Rio Preto - FAMERP*X*</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa Sao Lucas - IEP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01236-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital; Afdeling for Kræftbehandling</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Herning; Onkologisk afdeling</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Onkologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital, Onkologisk Afdeling R</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ain Shams University Hospital; Oncology</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPITAL JEAN MINJOZ; Oncologie</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Augustin Morvan; Federation De Cancerologie</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Estaing; Chir Generale Digestive A Et B</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique; Cancerologie</name>
      <address>
        <city>Levallois-Perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez; Medecine Interne Oncologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch De Montbeliard;Chir Generale Digestive</name>
      <address>
        <city>Montbeliard</city>
        <zip>25209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Caremeau; Gastro Enterologie</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine; Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu La Miletrie; Gastro Enterologie Endoscopies</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg; ICANS</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil; Gastro Enterologie Et Nutrition</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Departement Oncologie Medicale</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Praxis Dr. med. - Heinrich, - Bangerter</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Kurfürstendamm</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Berlin Köpenick Darmzentrum</name>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PIOH PD Dr. R. Schnell - Dr. H. Schulz - Dr. M. Hellmann</name>
      <address>
        <city>Frechen</city>
        <zip>50226</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum, Studienzentrale der II. Med. Klinik</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH Klinik für Innere Medizin III, Onkologisches Studienzentrum</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Ruhr-Uni Bochum; Marien-Hospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis; Onkologisches Zentrum Lebach; Caritas Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg Klinik für Gastroenterologie und Hepatologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gGmbH Klinik für Allgemein- und Viszeralchirurgie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum München GmbH Klinikum Neuperlach Klinik f.Hämatologie u.Onkologie</name>
      <address>
        <city>München</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg; Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper-Hospital, Medizinische Klinik I</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherziger Brüder; Klinik für Internistische Onkologie / Hämatologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg / Ermstalklinik</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie &amp; Onkologie</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken</name>
      <address>
        <city>Stade</city>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wetzlar-Braunfels, Klinik für Hämatologie/Onkologie und Palliativmedizin</name>
      <address>
        <city>Wetzlar</city>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agioi Anargyroi; 3Rd Dept. of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>145 64</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ General Hosp Heraklion; Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni Hospital of Ioannina; Oncology Dept.</name>
      <address>
        <city>Ioannina</city>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras Medical Oncology</name>
      <address>
        <city>Patras</city>
        <zip>265 04</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thermi Clinic; Oncology Clinic</name>
      <address>
        <city>Thermi Thessalonikis</city>
        <zip>570 01</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinic Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 22</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euromedical General Clinic of Thessaloniki; Oncology Department</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 45</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma; Oncologia Medica</name>
      <address>
        <city>Parma</city>
        <state>Emilia-Romagna</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena; Oncologia Medica A</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario &quot;Agostino Gemelli&quot;; U.O.C. Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas Gavazzeni;U.O. Oncologia Medica</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Puglia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U.I. VERONA-OSPEDALE POLICLINICO G.B. ROSSI BORGO ROMA;ONCOLOGIA MEDICA-d.U.</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia; Oncology</name>
      <address>
        <city>Distrito Federal</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Rodolfo Padilla Padilla A.C.</name>
      <address>
        <city>León</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oaxaca Site Management Organization</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancerologia de Queretaro; Oncologia</name>
      <address>
        <city>Queretaro, Queretaro</city>
        <zip>76090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ijsselland Ziekenhuis; Inwendige Geneeskunde</name>
      <address>
        <city>Capelle A/d IJssel</city>
        <zip>NL 2900 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis; Interne Geneeskunde</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina ZKHS; Inwendige Geneeskunde Afd.</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius locatie Leidsche Rijn</name>
      <address>
        <city>Utrecht</city>
        <zip>3543 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii</name>
      <address>
        <city>Kraków</city>
        <zip>30-688</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Klinika Gastroenterologii Onkologicznej</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUC; Servico de Oncologia Medica</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Oncologia Medica</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bashkirian Republican Clinical Oncology Dispensary</name>
      <address>
        <city>UFA</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology and Radiology of Serbia; Medical Oncology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny Onkologicky Ustav; Oddelenie klinickej onkologie E</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>POKO Poprad; Department of Oncology</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche; Servicio de Oncologia</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Central de Asturias; Servicio de Oncologia</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de Oncologia</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia; Servicio de Oncologia</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia; Servicio de Oncologia Medica</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro; Servicio de Oncologia</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Univ. de Alicante; Servicio de Oncologia</name>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia</name>
      <address>
        <city>Lerida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya; Servicio de Oncologia</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra; Servicio de Oncologia</name>
      <address>
        <city>Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Orense; Servicio de Oncologia</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia; Servicio de oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet; Servicio Oncologia</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes University Hospital, Skånes Department of Onclology</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital; Oncology - Radiumhemmet</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem University School of Medicine, Adana Hospital; General Surgery</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department</name>
      <address>
        <city>Edirne</city>
        <zip>22770</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Uni Capa Medical Faculty; Inst. of Oncology</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara Uni Faculty of Medicine; Medical Oncology</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Uni Medical Faculty Hospital; Oncology Dept</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Uni Medical Faculty Hospital; Oncology Dept</name>
      <address>
        <city>Sihhiye/Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary; Medical Oncology Dept</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital; Oncology</name>
      <address>
        <city>Chelsmford</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital; The Queens Centre for Oncology and Haematology</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas NHS Foundation Trust, Guys Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Dept of Med-Onc</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust; Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M2O 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Middlesex</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital; Medical Oncology</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Dept. of Medicine</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Cyprus</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <results_first_submitted>May 28, 2020</results_first_submitted>
  <results_first_submitted_qc>July 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2020</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02291289/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02291289/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Induction Phase (IP)</title>
          <description>Included participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib</title>
          <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
          <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 (IP)</title>
          <description>Included participants with BRAFwt. All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab</title>
          <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
          <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 3 (IP)</title>
          <description>Included participants with human epidermal growth factor receptor 2 positive (HER2+). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab</title>
          <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
          <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="P10">
          <title>Cohort 4 (IP)</title>
          <description>Included participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.</description>
        </group>
        <group group_id="P11">
          <title>Cohort 4 (MP): Cobimetinib,Atezolizumab</title>
          <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="P12">
          <title>Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
          <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="445"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="99"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="436"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="98"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Dosed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P2" count="40">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P3" count="20">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P4" count="0">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P5" count="297">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P6" count="148">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P7" count="0">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P8" count="3">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P9" count="2">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P10" count="0">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P11" count="65">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
                <participants group_id="P12" count="34">Participants from IP Cohorts were randomized to the MP Cohorts based on bio-marker assessments.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="293"/>
                <participants group_id="P6" count="143"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="64"/>
                <participants group_id="P12" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="34"/>
                <participants group_id="P12" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="252"/>
                <participants group_id="P6" count="129"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="31"/>
                <participants group_id="P12" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="185"/>
                <participants group_id="P6" count="100"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="26"/>
                <participants group_id="P12" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Multiple Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Treatment Received</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Included participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt)</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Included participants with BRAFwt</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Included participants with human epidermal growth factor receptor 2 positive (HER2+)</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4</title>
          <description>Included participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="445"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="99"/>
            <count group_id="B5" value="609"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="11.0"/>
                    <measurement group_id="B2" value="60.6" spread="12.3"/>
                    <measurement group_id="B3" value="49.6" spread="7.4"/>
                    <measurement group_id="B4" value="59.5" spread="10.2"/>
                    <measurement group_id="B5" value="60.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>In utero</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Preterm newborn infants (gestational age &lt; 37 wks)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Newborns (0-27 days)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Infants and toddlers (28 days-23 months)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Children (2-11 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adolescents (12-17 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adults (18-64 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="364"/>
                  </measurement_list>
                </category>
                <category>
                  <title>From 65-84 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>85 years and over</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian/Native Alaskan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="375"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>From randomization until death from any cause, up to 5 years</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <time_frame>From baseline until end of study (up to 5 years)</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS is defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.</description>
        <time_frame>From randomization until disease progression or death from any cause, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib</title>
            <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab</title>
            <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab</title>
            <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (MP): Cobimetinib,Atezolizumab</title>
            <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>PFS is defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="297"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.99" spread="7.72" lower_limit="7.72" upper_limit="12.55"/>
                    <measurement group_id="O2" value="11.60" spread="3.58" lower_limit="3.58" upper_limit="15.67"/>
                    <measurement group_id="O3" value="7.13" spread="6.14" lower_limit="6.14" upper_limit="8.41"/>
                    <measurement group_id="O4" value="7.36" spread="5.82" lower_limit="5.82" upper_limit="8.94"/>
                    <measurement group_id="O5" value="4.44" spread="3.55" lower_limit="3.55" upper_limit="14.69"/>
                    <measurement group_id="O6" value="4.04" spread="4.04" lower_limit="4.04" upper_limit="5.39"/>
                    <measurement group_id="O7" value="3.75" spread="3.42" lower_limit="3.42" upper_limit="3.91"/>
                    <measurement group_id="O8" value="7.79" spread="3.98" lower_limit="3.98" upper_limit="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.872</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.666</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.128</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response</title>
        <description>Calculated as the number of participants with a best overall response of CR or PR according to RECIST 1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR= CR + PR.</description>
        <time_frame>From randomization until disease progression, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib</title>
            <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control(MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab</title>
            <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab</title>
            <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (MP): Cobimetinib,Atezolizumab</title>
            <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response</title>
          <description>Calculated as the number of participants with a best overall response of CR or PR according to RECIST 1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR= CR + PR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="297"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.064</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.658</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.</description>
        <time_frame>From randomization until disease progression, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib</title>
            <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control(MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2(MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab</title>
            <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab</title>
            <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (MP): Cobimetinib,Atezolizumab</title>
            <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="297"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="227"/>
                    <measurement group_id="O4" value="111"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="44"/>
                    <measurement group_id="O8" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.125</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.739</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Response</title>
        <description>Calculated as the time from randomization to the first Occurrence of a documented Objective Response (CR or PR) determined according to RECIST 1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.</description>
        <time_frame>From randomization until disease progression or death from any cause, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib</title>
            <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control(MP):5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2(MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab</title>
            <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab</title>
            <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (MP): Cobimetinib,Atezolizumab</title>
            <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Response</title>
          <description>Calculated as the time from randomization to the first Occurrence of a documented Objective Response (CR or PR) determined according to RECIST 1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="297"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.943" lower_limit="1.18" upper_limit="29.70"/>
                    <measurement group_id="O2" value="5.552" lower_limit="1.38" upper_limit="8.02"/>
                    <measurement group_id="O3" value="5.224" lower_limit="1.22" upper_limit="26.74"/>
                    <measurement group_id="O4" value="4.616" lower_limit="1.25" upper_limit="19.91"/>
                    <measurement group_id="O5" value="5.490" lower_limit="5.490" upper_limit="5.490"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="3.745" lower_limit="1.77" upper_limit="14.92"/>
                    <measurement group_id="O8" value="2.530" lower_limit="1.64" upper_limit="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.</description>
        <time_frame>From first objective response until disease progression or death from any cause, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib</title>
            <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control(MP):5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2(MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab</title>
            <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab</title>
            <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (MP): Cobimetinib,Atezolizumab</title>
            <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="297"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" lower_limit="7.66" upper_limit="21.49"/>
                    <measurement group_id="O2" value="8.74" lower_limit="5.36" upper_limit="19.02"/>
                    <measurement group_id="O3" value="9.30" lower_limit="5.55" upper_limit="11.30"/>
                    <measurement group_id="O4" value="7.59" lower_limit="6.93" upper_limit="13.90"/>
                    <measurement group_id="O5" value="9.205" lower_limit="9.205" upper_limit="9.205"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="7.11" lower_limit="1.48" upper_limit="NA">Upper value of the 95% CI cannot be calculated because it is above the maximum value observed.</measurement>
                    <measurement group_id="O8" value="6.06" lower_limit="2.20" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.421</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.495</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.357</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score</title>
        <time_frame>From baseline until end of study (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib</title>
            <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control(MP):5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2(MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab</title>
            <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab</title>
            <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 (MP): Cobimetinib,Atezolizumab</title>
            <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
            <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="297"/>
                <count group_id="O4" value="148"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="10.4"/>
                    <measurement group_id="O4" value="5.4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="7.7"/>
                    <measurement group_id="O8" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved or stayed the same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="85.0"/>
                    <measurement group_id="O3" value="76.7"/>
                    <measurement group_id="O4" value="82.5"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="63.1"/>
                    <measurement group_id="O8" value="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline until end of study (up to 5 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Induction Phase (IP)</title>
          <description>Included participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib</title>
          <description>Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
          <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 (IP)</title>
          <description>Included participants with BRAFwt. All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab</title>
          <description>Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
          <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 3 (IP)</title>
          <description>Included participants with human epidermal growth factor receptor 2 positive (HER2+). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab</title>
          <description>Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
          <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 4 (IP)</title>
          <description>Included participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.</description>
        </group>
        <group group_id="E11">
          <title>Cohort 4 (MP): Cobimetinib,Atezolizumab</title>
          <description>Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.</description>
        </group>
        <group group_id="E12">
          <title>Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab</title>
          <description>Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="292" subjects_at_risk="436"/>
                <counts group_id="E5" subjects_affected="185" subjects_at_risk="293"/>
                <counts group_id="E6" subjects_affected="100" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="38" subjects_at_risk="98"/>
                <counts group_id="E11" subjects_affected="26" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="436"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="293"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E11" subjects_affected="25" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chorioretinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Immune-mediated enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Implant site dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Implant site thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Large intestine infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vascular device infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tracheal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Second primary malignancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tumour perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ureteral stent removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="415" subjects_at_risk="436"/>
                <counts group_id="E5" subjects_affected="270" subjects_at_risk="293"/>
                <counts group_id="E6" subjects_affected="118" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="96" subjects_at_risk="98"/>
                <counts group_id="E11" subjects_affected="61" subjects_at_risk="64"/>
                <counts group_id="E12" subjects_affected="27" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="41" subjects_affected="35" subjects_at_risk="436"/>
                <counts group_id="E5" events="25" subjects_affected="19" subjects_at_risk="293"/>
                <counts group_id="E6" events="13" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="11" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E11" events="8" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="32" subjects_affected="24" subjects_at_risk="436"/>
                <counts group_id="E5" events="8" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="149" subjects_affected="96" subjects_at_risk="436"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="293"/>
                <counts group_id="E6" events="18" subjects_affected="9" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="40" subjects_affected="25" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="35" subjects_affected="27" subjects_at_risk="436"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="293"/>
                <counts group_id="E6" events="10" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="8" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E12" events="5" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="16" subjects_affected="15" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E5" events="32" subjects_affected="24" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="63" subjects_affected="51" subjects_at_risk="436"/>
                <counts group_id="E5" events="44" subjects_affected="39" subjects_at_risk="293"/>
                <counts group_id="E6" events="16" subjects_affected="13" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="13" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E11" events="15" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E12" events="5" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="22" subjects_affected="19" subjects_at_risk="436"/>
                <counts group_id="E5" events="21" subjects_affected="17" subjects_at_risk="293"/>
                <counts group_id="E6" events="16" subjects_affected="12" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="104" subjects_affected="81" subjects_at_risk="436"/>
                <counts group_id="E5" events="47" subjects_affected="36" subjects_at_risk="293"/>
                <counts group_id="E6" events="27" subjects_affected="18" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" events="23" subjects_affected="20" subjects_at_risk="98"/>
                <counts group_id="E11" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dental cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="58"/>
                <counts group_id="E2" events="39" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" events="264" subjects_affected="158" subjects_at_risk="436"/>
                <counts group_id="E5" events="114" subjects_affected="74" subjects_at_risk="293"/>
                <counts group_id="E6" events="34" subjects_affected="19" subjects_at_risk="143"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="68" subjects_affected="33" subjects_at_risk="98"/>
                <counts group_id="E11" events="84" subjects_affected="40" subjects_at_risk="64"/>
                <counts group_id="E12" events="11" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="436"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="8" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="18" subjects_affected="11" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="436"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="60" subjects_affected="30" subjects_at_risk="58"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="295" subjects_affected="177" subjects_at_risk="436"/>
                <counts group_id="E5" events="126" subjects_affected="60" subjects_at_risk="293"/>
                <counts group_id="E6" events="42" subjects_affected="28" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="90" subjects_affected="43" subjects_at_risk="98"/>
                <counts group_id="E11" events="18" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E12" events="21" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Palatal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="111" subjects_affected="82" subjects_at_risk="436"/>
                <counts group_id="E5" events="48" subjects_affected="35" subjects_at_risk="293"/>
                <counts group_id="E6" events="19" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="21" subjects_affected="16" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="112" subjects_affected="82" subjects_at_risk="436"/>
                <counts group_id="E5" events="59" subjects_affected="38" subjects_at_risk="293"/>
                <counts group_id="E6" events="12" subjects_affected="9" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="31" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E11" events="15" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E12" events="8" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="109" subjects_affected="73" subjects_at_risk="436"/>
                <counts group_id="E5" events="57" subjects_affected="39" subjects_at_risk="293"/>
                <counts group_id="E6" events="20" subjects_affected="12" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="26" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E11" events="11" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="202" subjects_affected="132" subjects_at_risk="436"/>
                <counts group_id="E5" events="78" subjects_affected="54" subjects_at_risk="293"/>
                <counts group_id="E6" events="28" subjects_affected="23" subjects_at_risk="143"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="49" subjects_affected="34" subjects_at_risk="98"/>
                <counts group_id="E11" events="16" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E12" events="7" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="34" subjects_affected="31" subjects_at_risk="436"/>
                <counts group_id="E5" events="25" subjects_affected="19" subjects_at_risk="293"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="19" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="436"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="9" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="52" subjects_affected="43" subjects_at_risk="436"/>
                <counts group_id="E5" events="50" subjects_affected="31" subjects_at_risk="293"/>
                <counts group_id="E6" events="15" subjects_affected="13" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="13" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E11" events="23" subjects_affected="17" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E5" events="20" subjects_affected="15" subjects_at_risk="293"/>
                <counts group_id="E6" events="12" subjects_affected="10" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="13" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="436"/>
                <counts group_id="E5" events="20" subjects_affected="12" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="25" subjects_affected="21" subjects_at_risk="436"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="293"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="10" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="436"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="11" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="25" subjects_affected="19" subjects_at_risk="436"/>
                <counts group_id="E5" events="14" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E6" events="9" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="13" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="18" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="293"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="15" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="436"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="4" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="39" subjects_affected="32" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="436"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="5" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="7" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="68" subjects_affected="46" subjects_at_risk="436"/>
                <counts group_id="E5" events="10" subjects_affected="6" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="15" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="35" subjects_affected="23" subjects_at_risk="436"/>
                <counts group_id="E5" events="19" subjects_affected="6" subjects_at_risk="293"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="13" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E11" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="33" subjects_affected="32" subjects_at_risk="436"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="7" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="84" subjects_affected="64" subjects_at_risk="436"/>
                <counts group_id="E5" events="24" subjects_affected="22" subjects_at_risk="293"/>
                <counts group_id="E6" events="16" subjects_affected="15" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="17" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E11" events="11" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Food craving</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="29" subjects_affected="22" subjects_at_risk="436"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="5" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="7" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="436"/>
                <counts group_id="E5" events="10" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="10" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="43" subjects_affected="34" subjects_at_risk="436"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="293"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="436"/>
                <counts group_id="E5" events="53" subjects_affected="44" subjects_at_risk="293"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="436"/>
                <counts group_id="E5" events="32" subjects_affected="22" subjects_at_risk="293"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="293"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="436"/>
                <counts group_id="E5" events="17" subjects_affected="15" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="9" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="19" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E5" events="18" subjects_affected="13" subjects_at_risk="293"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="39" subjects_affected="30" subjects_at_risk="436"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="70" subjects_affected="38" subjects_at_risk="436"/>
                <counts group_id="E5" events="75" subjects_affected="23" subjects_at_risk="293"/>
                <counts group_id="E6" events="16" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="24" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E11" events="8" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="95" subjects_affected="67" subjects_at_risk="436"/>
                <counts group_id="E5" events="21" subjects_affected="18" subjects_at_risk="293"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="143"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="25" subjects_affected="18" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="5" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="20" subjects_affected="14" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="15" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="75" subjects_affected="63" subjects_at_risk="436"/>
                <counts group_id="E5" events="21" subjects_affected="18" subjects_at_risk="293"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="143"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="17" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="233" subjects_affected="153" subjects_at_risk="436"/>
                <counts group_id="E5" events="38" subjects_affected="32" subjects_at_risk="293"/>
                <counts group_id="E6" events="16" subjects_affected="15" subjects_at_risk="143"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="42" subjects_affected="28" subjects_at_risk="98"/>
                <counts group_id="E11" events="6" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="436"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="20" subjects_affected="19" subjects_at_risk="436"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="19" subjects_affected="17" subjects_at_risk="436"/>
                <counts group_id="E5" events="25" subjects_affected="17" subjects_at_risk="293"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="4" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="32" subjects_affected="30" subjects_at_risk="436"/>
                <counts group_id="E5" events="38" subjects_affected="30" subjects_at_risk="293"/>
                <counts group_id="E6" events="12" subjects_affected="10" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="35" subjects_affected="25" subjects_at_risk="436"/>
                <counts group_id="E5" events="17" subjects_affected="15" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="436"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="74" subjects_affected="68" subjects_at_risk="436"/>
                <counts group_id="E5" events="27" subjects_affected="22" subjects_at_risk="293"/>
                <counts group_id="E6" events="19" subjects_affected="15" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E10" events="19" subjects_affected="18" subjects_at_risk="98"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="17" subjects_affected="12" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="40" subjects_affected="40" subjects_at_risk="436"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E11" events="20" subjects_affected="18" subjects_at_risk="64"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="436"/>
                <counts group_id="E5" events="22" subjects_affected="19" subjects_at_risk="293"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="436"/>
                <counts group_id="E5" events="13" subjects_affected="12" subjects_at_risk="293"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nail ridging</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" events="30" subjects_affected="23" subjects_at_risk="436"/>
                <counts group_id="E5" events="64" subjects_affected="44" subjects_at_risk="293"/>
                <counts group_id="E6" events="40" subjects_affected="25" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="436"/>
                <counts group_id="E5" events="24" subjects_affected="19" subjects_at_risk="293"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E5" events="28" subjects_affected="23" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E11" events="32" subjects_affected="28" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="116" subjects_affected="90" subjects_at_risk="436"/>
                <counts group_id="E5" events="70" subjects_affected="49" subjects_at_risk="293"/>
                <counts group_id="E6" events="21" subjects_affected="16" subjects_at_risk="143"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="27" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="7" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

